{"id":"https://openalex.org/W2156136395","doi":"https://doi.org/10.1158/1078-0432.ccr-09-3220","title":"A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors","display_name":"A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors","publication_year":2010,"publication_date":"2010-04-07","ids":{"openalex":"https://openalex.org/W2156136395","doi":"https://doi.org/10.1158/1078-0432.ccr-09-3220","mag":"2156136395","pmid":"https://pubmed.ncbi.nlm.nih.gov/20371689"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-09-3220","doi":"https://doi.org/10.1158/1078-0432.ccr-09-3220","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-09-3220","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070570779","display_name":"Amita Patnaik","orcid":"https://orcid.org/0000-0002-4144-2193","observed_orcids":["https://orcid.org/0000-0002-4144-2193"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amita Patnaik","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054371540","display_name":"Joseph Aisner","orcid":"https://orcid.org/0000-0003-0662-7077","observed_orcids":["https://orcid.org/0000-0003-0662-7077"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Aisner","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Terri Warren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Terri Warren","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103144296","display_name":"Stephen Leong","orcid":"https://orcid.org/0000-0002-8838-8542","observed_orcids":["https://orcid.org/0000-0002-8838-8542"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Leong","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046099119","display_name":"Robert S. Benjamin","orcid":"https://orcid.org/0000-0002-2589-5870","observed_orcids":["https://orcid.org/0000-0002-2589-5870"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Benjamin","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046581734","display_name":"Sabine Eckhardt","orcid":"https://orcid.org/0000-0001-6958-5375","observed_orcids":["https://orcid.org/0000-0001-6958-5375"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Gail Eckhardt","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110319492","display_name":"Joseph E. Eid","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph E. Eid","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010960151","display_name":"G\u00e9rard Greig","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gerard Greig","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077077285","display_name":"Kai Habben","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kai Habben","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040437806","display_name":"Cinara D. McCarthy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cinara D. McCarthy","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5037169725","display_name":"Lia Gore","orcid":"https://orcid.org/0000-0002-2546-4616","observed_orcids":["https://orcid.org/0000-0002-2546-4616"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lia Gore","raw_affiliation_strings":["Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Anderson Cancer Center, Houston Texas; 2Institute for Drug Development, San Antonio, Texas; 3The Cancer Institute of New Jersey, Developmental Therapeutics Program, New Brunswick New Jersey; 4University of Colorado Cancer Center, Aurora, Colorado; 5Hoffmann-La Roche, Inc., Nutley, New Jersey; and 6Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I4390039325"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":20.0313,"has_fulltext":false,"cited_by_count":194,"citation_normalized_percentile":{"value":0.99610156,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"16","issue":"8","first_page":"2458","last_page":"2465"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10748","display_name":"Growth Hormone and Insulin-like Growth Factors","score":0.9320999979972839,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10748","display_name":"Growth Hormone and Insulin-like Growth Factors","score":0.9320999979972839,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.038100000470876694,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.004100000020116568,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.9390000104904175},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9120000004768372},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9240000247955322},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9890000224113464},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8840000033378601},{"id":"https://openalex.org/keywords/once-weekly-dosing","display_name":"weekly dosing","score":0.6179999709129333},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7929999828338623},{"id":"https://openalex.org/keywords/ewing-sarcoma","display_name":"Ewing sarcoma","score":0.9309999942779541},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8939999938011169}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7978509068489075},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7792667150497437},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7095329761505127},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6879013180732727},{"id":"https://openalex.org/C2778256501","wikidata":"https://www.wikidata.org/wiki/Q223911","display_name":"Sarcoma","level":2,"score":0.5814968943595886},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.5480431318283081},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.533022403717041},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.48663434386253357},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.46351563930511475},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.45030486583709717},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4480147063732147},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.44587987661361694},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4418051838874817},{"id":"https://openalex.org/C2776146153","wikidata":"https://www.wikidata.org/wiki/Q7281276","display_name":"Radioimmunotherapy","level":4,"score":0.43951427936553955},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.38013631105422974},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.37133878469467163},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.31962740421295166},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2993771731853485},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.21732115745544434},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.19853147864341736},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.1866183578968048}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017526","descriptor_name":"Receptor, IGF Type 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.ccr-09-3220","doi":"https://doi.org/10.1158/1078-0432.ccr-09-3220","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-09-3220","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:20371689","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20371689","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:alma.01RUT_INST:11663508040004646","doi":null,"is_oa":false,"landing_page_url":"https://scholarship.libraries.rutgers.edu/esploro/outputs/journalArticle/A-phase-I-study-of-weekly/991031654630104646","pdf_url":null,"source":{"id":"https://openalex.org/S4306401388","display_name":"Rutgers University Community Repository (Rutgers University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I102322142","host_organization_name":"Rutgers, The State University of New Jersey","host_organization_lineage":["https://openalex.org/I102322142"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8100000023841858}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":39,"referenced_works":["https://openalex.org/W1495077531","https://openalex.org/W1600831499","https://openalex.org/W2008585163","https://openalex.org/W2020636054","https://openalex.org/W2023910639","https://openalex.org/W2039144093","https://openalex.org/W2039313774","https://openalex.org/W2040461176","https://openalex.org/W2044826176","https://openalex.org/W2054711858","https://openalex.org/W2062797909","https://openalex.org/W2063424356","https://openalex.org/W2070001236","https://openalex.org/W2080508038","https://openalex.org/W2081636946","https://openalex.org/W2086941386","https://openalex.org/W2089171551","https://openalex.org/W2094926346","https://openalex.org/W2107837604","https://openalex.org/W2112474467","https://openalex.org/W2121434969","https://openalex.org/W2139248078","https://openalex.org/W2141163594","https://openalex.org/W2144428065","https://openalex.org/W2150081825","https://openalex.org/W2151444534","https://openalex.org/W2151765511","https://openalex.org/W2158239112","https://openalex.org/W2167156722","https://openalex.org/W2246578212","https://openalex.org/W2253720089","https://openalex.org/W2264947172","https://openalex.org/W2411227825","https://openalex.org/W2532022854","https://openalex.org/W4245654064","https://openalex.org/W6629470835","https://openalex.org/W6680765157","https://openalex.org/W6693108930","https://openalex.org/W6715069820"],"related_works":["https://openalex.org/W2512096769","https://openalex.org/W2050416697","https://openalex.org/W2264947172","https://openalex.org/W2532022854","https://openalex.org/W2734688671","https://openalex.org/W1993624360","https://openalex.org/W1976269797","https://openalex.org/W2155000185","https://openalex.org/W1547298604","https://openalex.org/W2339772802"],"abstract_inverted_index":{"PURPOSE:":[0],"A":[1],"phase":[2],"I":[3],"study":[4,73],"was":[5,104,147],"conducted":[6],"to":[7,40,136],"evaluate":[8],"the":[9,25,72,75,100,139,183,212],"pharmacokinetics,":[10],"pharmacodynamics,":[11],"safety,":[12],"and":[13,56,99,117,161,174,195],"tolerability":[14],"of":[15,77,109,120,159,167],"R1507-a":[16],"fully":[17],"human":[18,26],"IgG1":[19],"type":[20],"monoclonal":[21],"antibody":[22],"directed":[23],"against":[24],"insulin-like":[27],"growth":[28],"factor-I":[29],"receptor.":[30],"EXPERIMENTAL":[31],"DESIGN:":[32],"Patients":[33,69],"with":[34,47,91,122,153,201],"advanced":[35],"solid":[36,202],"tumors":[37],"were":[38,52,89,97,111],"assigned":[39],"receive":[41],"i.v.":[42],"R1507":[43,67,92,110,146,191],"weekly":[44,128,213],"(qW),":[45],"starting":[46],"1":[48],"mg/kg.":[49,59],"Subsequent":[50],"cohorts":[51],"dosed":[53],"at":[54,165],"3":[55],"then":[57],"9":[58,65,216],"An":[60],"additional":[61],"12":[62],"patients":[63,88,151,170,200],"received":[64],"mg/kg":[66,217],"qW.":[68,93,218],"remained":[70],"on":[71],"until":[74],"development":[76],"a":[78,114],"dose-limiting":[79,95],"toxicity":[80],"or":[81],"progressive":[82,177],"disease.":[83],"RESULTS:":[84],"In":[85],"total,":[86],"37":[87],"treated":[90],"No":[94],"toxicities":[96],"identified":[98],"maximum":[101],"tolerated":[102,194],"dose":[103,137,210],"not":[105],"reached.":[106],"The":[107,208],"pharmacokinetics":[108],"characterized":[112],"by":[113,182],"slow":[115],"clearance":[116],"limited":[118],"volume":[119],"distribution,":[121],"an":[123],"estimated":[124],"elimination":[125],"half-life":[126],"justifying":[127],"administration.":[129],"Serum":[130],"IGF-I":[131],"ligand":[132],"levels":[133],"increased":[134],"proportionally":[135],"during":[138],"first":[140],"72":[141],"hours":[142],"in":[143,187,199,204],"all":[144],"cohorts.":[145],"well":[148,193],"tolerated.":[149],"Two":[150],"diagnosed":[152],"Ewing's":[154,206],"sarcoma":[155],"had":[156,171,176],"partial":[157],"responses":[158],"11.5":[160],">26":[162],"months":[163],"(ongoing":[164],"time":[166],"submission);":[168],"13":[169],"stable":[172],"disease;":[173],"16":[175],"disease":[178],"as":[179],"best":[180],"response":[181],"Response":[184],"Evaluation":[185],"Criteria":[186],"Solid":[188],"Tumors.":[189],"CONCLUSION:":[190],"is":[192,215],"shows":[196],"antitumor":[197],"activity":[198],"neoplasms,":[203],"particular":[205],"sarcoma.":[207],"recommended":[209],"for":[211],"schedule":[214]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":13},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":16},{"year":2013,"cited_by_count":21},{"year":2012,"cited_by_count":23}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}